Brief: Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202
05/08/2025 14:31
Aug 5 (Reuters) - Senti Biosciences Inc SNTI.O: SENTI BIO DETERMINES RECOMMENDED PHASE 2 DOSE (RP2D) IN PHASE 1 STUDY OF SENTI-202 FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA SENTI BIOSCIENCES INC - SENTI-202 WELL-TOLERATED, NO DOSE LIMITING TOXICITIES SENTI BIOSCIENCES - EXPECTS TO REPORT CLINICAL DATA, INCLUDING EFFICACY & DURABILITY, FROM EXPANSION COHORT BEFORE YEAR-END Source text: ID:nGNX5LcXv7 Further company coverage: SNTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates